Survival in patients with HR+/HER2- metastatic breast cancer treated with initial endocrine therapy versus initial chemotherapy. A French population-based study.
Julien SimonMarie ChaixOumar BillaAriane Mamguem KamgaPatrick RoignotSylvain LadoireCharles CoutantPatrick ArveuxCatherine QuantinTienhan Sandrine Dabakuyo-YonliPublished in: British journal of cancer (2020)
This study shows that treating patients with HR+/HER2- metastatic breast cancer with initial ET could provide a survival advantage in comparison with initial CT.